The Supreme Court of the US has ruled that the abortion pill mifepristone can continue to be prescribed remotely and ...

UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...

Khalil Asmar, VP of cardiometabolic health at Lilly UK & Ireland (l), and former England spin bowler Ashley Giles (r). Like ...

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its approved therapy for the sleep disorder narcolepsy. Lundbeck's ...

Regeneron's bid to join the US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised after the FDA approved its Lynozyfic drug at a second attempt. Lynozyfic ...

The UK life sciences raised £1.23 billion ($1.65 billion) in venture capital investment in the first half of 2025, putting it on course to at least match the 2024 total for the full year. That's the ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, ...

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...

Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...

Embattled UK Prime Minister Sir Keir Starmer has put changes to the health service on the legislative programme in today's ...